APR-246 (eprenetapopt) + Acalabrutinib in CLL
A20-11197
Phase 2 small_molecule terminated
Quick answer
APR-246 (eprenetapopt) + Acalabrutinib in CLL for Non Hodgkin Lymphoma is a Phase 2 program (small_molecule) at Aprea Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Aprea Therapeutics
- Indication
- Non Hodgkin Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated